Search research articles
Contact Us
Filters
Showing results (161-170 of 186) with videos related to
Page
of 19
Sort By:
The Oncologist
|
May 30, 2024
Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial
Julia L Glade Bender, Kerice Pinkney, Paul M Williams, et al.
Journal of the National Cancer Institute
|
May 25, 2023
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C
Susan N Chi, Joanna S Yi, P Mickey Williams, et al.
The Oncologist
|
June 14, 2024
Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G
Marie V Nelson, AeRang Kim, P Mickey Williams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 4, 2023
Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents
Lucas Moreno, Steven G DuBois, Julia Glade Bender, et al.
JCO Precision Oncology
|
October 30, 2025
Germline Cancer Predisposition Results From the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial
Sarah Scollon, Sharon E Plon, Steven Joffe, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 18, 2021
Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE
Andrew Dj Pearson, Steven G DuBois, Vickie Buenger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2018
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
Steven G DuBois, Yael P Mosse, Elizabeth Fox, et al.
JCO Precision Oncology
|
January 15, 2026
Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis
Susanne A Gatz, Julia Glade-Bender, Andrew D J Pearson, et al.
Neuro-Oncology
|
April 8, 2022
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
Ami V Desai, Giles W Robinson, Karen Gauvain, et al.
The Lancet. HIV
|
August 29, 2025
Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial
Patrice Severe, Samuel Pierre, Fabienne Homeus, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 186) with videos related to
Sort By:
Page
of 19
The Oncologist
|
May 30, 2024
Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial
Julia L Glade Bender, Kerice Pinkney, Paul M Williams, et al.
Journal of the National Cancer Institute
|
May 25, 2023
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C
Susan N Chi, Joanna S Yi, P Mickey Williams, et al.
The Oncologist
|
June 14, 2024
Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G
Marie V Nelson, AeRang Kim, P Mickey Williams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 4, 2023
Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents
Lucas Moreno, Steven G DuBois, Julia Glade Bender, et al.
JCO Precision Oncology
|
October 30, 2025
Germline Cancer Predisposition Results From the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial
Sarah Scollon, Sharon E Plon, Steven Joffe, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 18, 2021
Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE
Andrew Dj Pearson, Steven G DuBois, Vickie Buenger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2018
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
Steven G DuBois, Yael P Mosse, Elizabeth Fox, et al.
JCO Precision Oncology
|
January 15, 2026
Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis
Susanne A Gatz, Julia Glade-Bender, Andrew D J Pearson, et al.
Neuro-Oncology
|
April 8, 2022
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
Ami V Desai, Giles W Robinson, Karen Gauvain, et al.
The Lancet. HIV
|
August 29, 2025
Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial
Patrice Severe, Samuel Pierre, Fabienne Homeus, et al.
Page
of 19